|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,111.00 GBX | -0.19% |
|
-2.35% | +15.98% |
| 03:35pm | GSK outgoing CEO Emma Walmsley's 2025 total remuneration was 15.7 mln pounds vs 10.6 mln pounds in 2024 - annual report | RE |
| 04/03 | When Talk of Talks Moves Markets |  |
| Capitalization | 8.48TCr 11TCr 9.74TCr 8.84TCr 15TCr 10,44400Cr 16TCr 1,03900Cr 42TCr 4,98100Cr 43TCr 42TCr 17,78900Cr | P/E ratio 2025 |
12.9x | P/E ratio 2026 * | 13.3x |
|---|---|---|---|---|---|
| Enterprise value | 9.89TCr 13TCr 11TCr 10TCr 18TCr 12,18500Cr 19TCr 1,21200Cr 49TCr 5,81100Cr 50TCr 49TCr 20,75400Cr | EV / Sales 2025 |
2.68x | EV / Sales 2026 * | 2.86x |
| Free-Float |
94.52% | Yield 2025 |
3.62% | Yield 2026 * | 3.28% |
Last Transcript: GSK plc
| 02/03 | GSK : Sell rating from JP Morgan | ZD |
| 02/03 | Price targets raised for BP and Shell | AN |
| 26/02 | GSK : Jefferies reiterates its Buy rating | ZD |
| 26/02 | GSK : Barclays reaffirms its Sell rating | ZD |
| 26/02 | GSK : Gets a Neutral rating from UBS | ZD |
| 1 day | -0.17% | ||
| 1 week | -2.35% | ||
| Current month | -3.86% | ||
| 1 month | -2.94% | ||
| 3 months | +17.23% | ||
| 6 months | +43.36% | ||
| Current year | +15.98% |
| 1 week | 2,106 |  | 2,201.13 |
| 1 month | 2,106 | | 2,282 |
| Current year | 1,774 | | 2,282 |
| 1 year | 1,242.5 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
| Chief Tech/Sci/R&D Officer | - | 01/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 68 | 01/09/2019 |
Charles Bancroft
BRD | Director/Board Member | 66 | 01/05/2020 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -0.85% | 3.15% | 26 M€ | |
| +4.23% | 2.97% | 64 M€ | |
| +8.17% | 2.51% | 8 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.19% | -2.35% | +42.68% | +47.01% | 11TCr | |
| -0.41% | -2.46% | +10.15% | +215.16% | 90TCr | |
| -0.59% | +0.05% | +48.29% | +59.27% | 59TCr | |
| +1.00% | +4.09% | +13.68% | +51.35% | 42TCr | |
| -1.38% | -2.34% | +17.12% | +31.18% | 37TCr | |
| -0.52% | -0.36% | +24.82% | +40.16% | 31TCr | |
| -1.50% | -1.45% | +26.24% | +59.35% | 31TCr | |
| +0.38% | -1.78% | +29.95% | +12.54% | 30TCr | |
| +0.60% | -1.32% | +21.49% | +61.52% | 20TCr | |
| +0.26% | +0.75% | +29.18% | +82.83% | 18TCr | |
| Average | -0.46% | -1.03% | +26.36% | +66.04% | 36.97TCr | |
| Weighted average by Cap. | -0.55% | -0.91% | +24.10% | +88.94% |
| 2025 | 2026 * | |
|---|---|---|
| Net sales | 3.25TCr 4.34TCr 3.74TCr 3.39TCr 5.94TCr 4,00400Cr 6.15TCr 40TCr 16TCr 1,91000Cr 16TCr 16TCr 6,82000Cr | 3.38TCr 4.52TCr 3.88TCr 3.52TCr 6.17TCr 4,16400Cr 6.4TCr 41TCr 17TCr 1,98600Cr 17TCr 17TCr 7,09200Cr |
| Net income | 569.92Cr 761.54Cr 654.84Cr 594.25Cr 1.04TCr 70TCr 1.08TCr 6.98TCr 2.8TCr 33TCr 2.86TCr 2.8TCr 1,19600Cr | 631.15Cr 843.35Cr 725.2Cr 658.09Cr 1.15TCr 78TCr 1.19TCr 7.73TCr 3.1TCr 37TCr 3.17TCr 3.1TCr 1,32400Cr |
| Net Debt | 1.41TCr 1.89TCr 1.62TCr 1.47TCr 2.58TCr 1,74100Cr 2.67TCr 17TCr 6.93TCr 83TCr 7.09TCr 6.94TCr 2,96500Cr | 1.2TCr 1.6TCr 1.38TCr 1.25TCr 2.19TCr 1,47600Cr 2.27TCr 15TCr 5.88TCr 70TCr 6.01TCr 5.88TCr 2,51400Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/26/05 | 2,116.00 p | +0.05% | 8,01,502 |
| 04/26/04 | 2,115.00 p | -0.33% | 63,23,059 |
| 03/26/03 | 2,122.00 p | -2.66% | 66,90,212 |
| 02/26/02 | 2,180.00 p | -0.95% | 69,66,860 |
| 27/26/27 | 2,201.00 p | +1.57% | 1,41,08,340 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition